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Introduction: Gestational Diabetes Mellitus (GDM) development is related to underlying
metabolic syndrome that is associated with elevated complement C3 and C4. Elevated
C3 levels have been associated with preeclampsia and the development of macrosomia.
Methods: This case-control study included 34 pregnant women with GDM and 16 non-
diabetic (ND) women in their second trimester. Complement-related proteins were
measured and correlated with demographic, biochemical, and pregnancy outcome data.
Results: GDM women were older with a higher BMI (p<0.001); complement C3, C4 and
Factor-H were significantly elevated (p=0.001, p=0.05, p=0.01, respectively). When
adjusted for age and BMI, Complement C3 (p=0.04) and Factor-H (p=0.04) remained
significant. Partial correlation showed significant correlation between C4 with serum alanine
aminotransferase (ALT) (p<0.05) and 2nd term diastolic blood pressure (p<0.05); Factor-H
and C-reactive protein (CRP; p<0.05). Pearson bivariate analysis revealed significant
correlations between C3, C4, and Factor-H and CRP; p<0.05; C3 and gestational age at
delivery (GA; p<0.05); C4 and ALT and second-trimester systolic blood pressure (STBP)
(p=0.008 and p<0.05, respectively); Factor-H and glycated hemoglobin (HbA1c) (p<0.05).
Regression analysis showed that the elevation of C3 could be accounted for by age, BMI,
GA and CRP, with CRP being the most important predictor (p=0.02). C4 elevation could be
accounted for by ALT, CRP and STBP. CRP predicted Factor-H elevation.
Conclusion: The increased C3, C4 and Factor-H during the second trimester of
pregnancy in GDM are not independently associated with GDM; inflammation and high
BMI may be responsible for their elevation. The elevation of second trimester C3 in GDM is
associated with earlier delivery and further work is needed to determine if this is predictive.
Keywords: complement, pregnancy, gestational diabetes, type 2 diabetes, preterm deliveryn.org March 2021 | Volume 12 | Article 6413611
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Gestational diabetes (GDM) is the most frequent pregnancy-
associated metabolic disorder, occurring in 14% of pregnant
women (1, 2). GDM is usually identified in the latter stage of the
second trimester (3). GDM is associated with increased risk of
complications for both the mother and the fetus, including
preterm delivery, cesarean delivery, preeclampsia, macrosomia,
shoulder dystocia, neonatal hypoglycaemia and respiratory
distress syndrome (4, 5). Women with a history of GDM are at
increased risk for cardiovascular disease (6) and type 2 diabetes
(T2DM) (7, 8) later in life.
During pregnancy, the nutritional demands of the fetus cause
a physiological increase in insulin resistance in the mother (9). In
a healthy pregnancy, compensatory mechanisms cause an
increase in glucose-stimulated insulin release (10) together
with an adaptive increase in beta-cell mass (11) to
counterbalance the increase in insulin resistance. However, in
pregnant women who are overweight or obese, insulin
requirements are increased and, if the demand exceeds the
insulin-secretory capacity, these conditions can increase risk
for GDM (12). Complex, and not yet fully elucidated,
mechanisms drive the pregnancy-related insulin resistance;Frontiers in Endocrinology | www.frontiersin.org 2notable factors are placental hormones, obesity, inactivity, poor
diet, and genetics/epigenetics (13).
Older maternal age, pre-gravid overweight or obese status
(14, 15), multiparity, ethnicity, a family history of diabetes, and
excessive gestational weight gain (16) are recognized risk factors
for the development of GDM.
Biomarkers that could predict GDM and its complications
earlier in pregnancy than is currently possible using the standard
oral glucose tolerance test would offer practical benefit for patient
care and may provide a deeper understanding of the biochemical
pathways involved in GDM and whether they parallel, or are
divergent from, those in T2DM.
Pregnancy presents a unique immunologic state that initiates
in earnest at implantation and usually resolves after delivery.
Similarly, GDM is a unique metabolic state that begins and ends
with gestation. The immunological changes that occur during
normal and in GDM women during pregnancy is not clearly
understood. The evolutionarily conserved complement system
protects the host against bacterial infection, the individual
elements forming a serine-protease cascade that attacks the
membranes of invading organisms and induces cell lysis;
hence, this system has been most studied in the context of
infectious diseases (Figure 1). Though less well defined, theFIGURE 1 | Complement activation pathways. Schematic illustration of classical (left panel), lectin (middle panel), and alternative (right panel) pathways of
complement activation, showing links between initiator molecules, proteases and C3, C5 convertases. Upward red arrows indicate the complements that are
elevated in the second trimester of pregnancy in gestational diabetes (GDM).March 2021 | Volume 12 | Article 641361
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is essential for homeostasis of host cells, removal of apoptotic
cells and priming of the adaptive immune response (17),
processes which all occur in normal pregnancy and which may
be dysregulated in pregnancies accompanied by metabolic
disorders, such as GDM, and preeclampsia (17).
In normal pregnancy, increased activation of the complement
system occurs with elevated plasma concentrations of C3a, C4a, and
C5a (18), which may be important to counterbalance the normal
suppression of adaptive immunity during pregnancy. Regulatory T
cells enable fetal tolerance and complement activation controls T
cell development (19, 20). Notably, preeclampsia has a well-known
association with complement activation (21–25) though which
regulatory T cells are decreased (26, 27). Factor D concentrations
are increased (22). Complement activation, specifically factors C3,
C4, C3a, Factor-H and Properdin, are associated with increased
incident metabolic syndrome (28); and complement activation
was related to adverse pregnancy outcomes, such as intrauterine
growth retardation and GDM (24, 29). Further, polymorphisms of
the mannose-binding lectin gene are associated with a higher risk
for GDM (21). At term, patients with GDM have lower levels of
C3a, C4a and C5a (30).
Given the elevation of complement in normal pregnancy we
hypothesized that there would be further dysregulation of the
complement system in GDM. Therefore, in this study, we sought
to determine the serum complement protein concentrations in
second trimester pregnant women with and without GDM and
their relationship to patient demographics, biochemical
parameters and pregnancy outcomes.MATERIALS AND METHODS
Study Design
This was a case-control study in 50 pregnant women (34 GDM and
16 non-diabetic (ND)) who were recruited during their second
trimester at the antenatal clinic at the Women Wellness and
Research Centre (WWRC) of Hamad Medical Corporation
(HMC), Doha, Qatar, during 2016-2017. The study protocols
were approved by the Institutional Review Boards (IRBs) of HMC
(15101/15) and Weill Cornell Medical College in Qatar (WCMQ)
(15-00016). Pregnant women between the ages of 18 and 40 without
any previous medical history of chronic disease, in the second
trimester of pregnancy and willing to comply with all study
procedures and be available for the duration of the study were
included. Pregnant women who are unable to provide informed
consent, who were in first or third trimester of pregnancy, or
currently enrolled in other clinical trials were excluded.
Demographics, anthropometrics, and medical history data
were collected, including age, ethnicity, socio-economic
background, vital signs, height, weight, menstrual cycle, the
period of infertility, medications, complications, comorbidities,
and familymedical history. According toQatar national guidelines
for GDM, all pregnant women are screened at the first antenatal
care visit by measuring fasting blood glucose (FBG). If FBG at the
first visit was >5.1 mmol/l (92 mg/dl), 75 g OGTT is performed at
24 weeks’ gestation. The WHO criteria [FBG ≥5.1 mmol/L (92Frontiers in Endocrinology | www.frontiersin.org 3mg/dl), 1-h post OGTT ≥10.0 mmol/L (180 mg/dl) or 2-h post
OGTT ≥8.5 mmol/L (153 mg/dl)] were used for GDM diagnosis.
GDM patients were seen back in the outpatient clinic within 1
week of the laboratory diagnosis of GDM. During this time blood
samples were collected for complement proteins measurement.
GDM patients were started on a diet for two weeks to achieve an
FBG ≤ 5.3 mmol/l (95 mg/dl) and a 2-h post-prandial glucose ≤
6.8 mmol/l (120 mg/dl) in ≥ 80% of the readings. If more than 20%
of the readings were above targets, then metformin therapy was
initiated and increased incrementally, followed by insulin
supplementation if glucose targets were not achieved.
Collection and Analysis of Blood Samples
Blood samples were collected and immediately processed and
stored frozen at −80°C pending analysis, as previously reported
(31). C reactive protein (CRP) was measured using magnetic bead
based multiplex assay (BIO-RAD, Hertfordshire, U.K detection
range 12 – 0.013 ng/ml, intra-assay CV 4% and inter-assay CV
6%). Analytical measurements for lipid parameters were total
cholesterol (reference range: <5.17 mmol/L desirable; 5.17–
6.18 mmol/L borderline high; >6.18 mmol/L high; clinical
reportable range: 0.16 – 72 mmol/L CV 0.8%), triglycerides
(reference range; normal <1.70 mmol/L; borderline high 1.70 –
2.2 mmol/L; high 2.2 -5.6 mmol/L; >5.6 mmol/L very high; clinical
reportable range: 0.07 – 100 mmol/L CV 1.6%), and high-density
lipoprotein cholesterol (HDL-C) (reference range above 1.0
mmol/L; clinical reportable range: 0.13 – 6.2 mmol/L; CV 2.6%)
levels were measured using an ARCHITECT c Systems (Abbott
Laboratories Sittingbourne, U.K) and measured in the Chemistry
Laboratory at Hamad Medical Corporation, Doha, Qatar, using
the manufacturer’s recommended protocol. Low-density
lipoprotein cholesterol (LDL-C) (reference range: desirable <
3.36 mmol/L; borderline 3.36–4.11 mmol/L; high risk > 4.12
mmol/L; clinical reportable range 0.03 – 50 mmol/L; CV 2.1%)
was calculated using the Friedewald equation. The analytical
measurement range for ALT (reference range 0 – 55; clinical
reportable range 5–4,700 U/L; CV 1.4%) and AST (reference range
5–34 U/L; clinical reportable range 2–4,565; CV 1%). HbA1c (4.2–
20.1%) was determined by enzymatic method on ARCHITECT c
Systems (clinical reportable range 4.2–20.1%; normal range: up to
5.6%, impaired glucose: 5.7–6.4%, diabetes: ≥ 6.5%; Abbott
Laboratories Sittingbourne, U.K). Serum insulin was assayed
using a competitive chemiluminescent immunoassay performed
on the manufacturer’s DPC Immulite 2000 analyzer (Euro/DPC,
Llanberis, UK). The analytical sensitivity of the insulin assay was 2
mU/ml, the coefficient of variation was 6%, and there was no stated
cross-reactivity with proinsulin. Plasma glucose was measured
using a Synchron LX 20 analyzer (Beckman-Coulter), using the
manufacturer’s recommended protocol. The coefficient of
variation for the assay was 1.2% at a mean glucose value of 5.3
mmol/L during the study period.
All patients gave written informed consent, and the conduct of
the study was in accordance with ICH GCP and the Declaration of
Helsinki. Pregnancy outcomes of gestational age at delivery, birth
weight, maternal weight, blood pressure, and fetal outcome were
recorded and collated with the apolipoprotein profile for all
subjects who participated in the study.March 2021 | Volume 12 | Article 641361
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Measurements
Complement proteins were determined using the MILLIPLEX
MAP Kit Human Complement Magnetic Bead Panel 1 (Cat #
HCMP1MAG-19K) and MILLIPLEX MAP Kit Human
Complement Magnetic Bead Panel 2 (Cat # HCMP2MAG-
19K, Merck Millipore, USA). Milliplex kits are sensitive
magnetic bead-based multiplexing protein panels that measure
quantitative levels of these proteins simultaneously in serum
samples. Complement protein levels in the samples were
quantitated by the 5PL (five parameters) logistic regression
algorithms that are built into the Bioplex manager six software,
which were used for quantification of all serum samples in
reference to standards. All the protein measurements were run
on a Bioplex-200 (BIO-RAD, Hertfordshire, U.K.) instrument.
The serum samples were diluted 200 times for complement panel
1 panel protein (C2, C4b, C5, C5a, C9, Factor D, Mannose-
Binding Lectin and Factor I) and 40,000 times for complement
panel 2 (C1q, C3, C3b/iC3b, C4, Factor B, Factor H and
Properdin) to the protein levels within the reference range of
the standard curve. The working range and assay precision for
different Complement proteins were as follows C9 (41.2–30,000
ng/ml, intra-assay CV <10% and intra-assay CV <10%), Factor D
(0.069–50 ng/ml, intra-assay CV <10% and intra-assay CV
<10%), Mannose-Binding Lectin (0.137–100 ng/ml, intra-assay
CV <10% and intra-assay CV <10%), Factor I (0.69–500 ng/ml,
intra-assay CV <10% and intra-assay CV <10%), C2 (1.37–1,000
ng/ml, intra-assay CV <10% and intra-assay CV <10%), C4b
(1.37 1000 ng/ml, intra-assay CV <10% and intra-assay CV
<10%), C5 (2.74–2,000 ng/ml, intra-assay CV <10% and intra-
assay CV <10%), C5a (4.12–3,000 ng/ml, intra-assay CV <10%
and intra-assay CV <20%), C1q (0.08–60 ng/ml, intra-assay CV
<10% and intra-assay CV <10%), C3 (0.27–200 ng/ml, intra-
assay CV <10% and intra-assay CV <20%), C3b/iC3b (8.2–6,000
ng/ml, intra-assay CV <10% and intra-assay CV <20%), C4
(0.55–400 ng/ml, intra-assay CV <10% and intra-assay CV
<10%), Factor B (0.08–60 ng/ml, intra-assay CV <10% and
intra-assay CV <10%), Factor H (0.41–300 ng/ml, intra-assay
CV <10% and intra-assay CV <10%) and Properdin (0.013–10
ng/ml, intra-assay CV <10% and intra-assay CV <20%).
Statistical Analysis
There was no specific study on second trimester complement
levels on which to power the study; however, given that GDM
has many features of the metabolic syndrome, C3 differences
between those with and without metabolic syndrome were used
(28). An alpha of 0.05 with 80% power gave an effect size of 1.07,
requiring a minimum of 15 subjects per group. (nQuery, Statsol
USA). Descriptive statistics and means ± standard deviations
(SD) were calculated for all continuous variables in the study. A
general linear model was used to compare mean differences
between control and GDM groups before and after adjustment
for age and BMI. Pearson and partial correlations were
performed to understand the associations between complement
variables and demographic variables, with the partial correlations
adjusted for age and BMI. Linear regression analysis was
performed to determine predictors for circulating C3, C4 andFrontiers in Endocrinology | www.frontiersin.org 4Factor-H. All statistical analysis was done using statistical
analysis SAS version 9.4 software. A statistical significance level
(P-value) of <0.05 was considered as significant.
RESULTS
Demographic and Biochemical
Characteristics of Study Participants
Compared to the ND women, the GDM women were older
(34.3 ± 4.4 vs 29.7 ± 4.2 years, p=0.001) and had a higher BMI
(35.3 ± 5.6 vs 28.4 ± 6.4 kg/m2, GDM vs ND, p=0.0003). Baseline
systolic and diastolic blood pressure were comparable between
the 2 groups. GDM was diagnosed at 22.2 ± 4.1 weeks, and the
control women were matched for gestational age (p=0.308). In
keeping with the diagnosis, fasting plasma glucose was elevated
in the GDM women (5.5 ± 0.9 vs 4.7 ± 0.3, GDM vs ND,
p=0.039), though insulin and HbA1c did not differ between
groups, indicative of the recent onset of hyperglycemia in the
GDM women. Lipids (cholesterol, triglycerides, high- and low-
density lipoproteins) and CRP did not differ between the cohorts,
while ALT was elevated in the GDM women (17.5 ± 11.8 vs
10.2 ± 3.6 U/l, GDM vs ND, p=0.005).There were two premature
deliveries in the control and five in the GDM group and no infant
was LGA in our cohort. Gestational age at delivery and baby
weight were similar between the cohorts (Table 1).
Complement Proteins
Complement C3 (279 ± 126 vs 162 ± 56 µg/ml, GDM vs ND,
p=0.001), complement C4 (550 ± 96 vs 487 ± 105 µg/ml, GDM vs
ND, p=0.05) and Factor-H (358 ± 57 vs 310 ± 66 µg/ml, GDM vs
ND, p=0.01) were all elevated in the GDM women compared
with ND women. Complement C1q, Factor-B, Properdin and the
Anti-complement proteins were not different between the two
cohorts (Table 2). After adjustment for age and BMI, only
complement C3 (p=0.04) and Factor-H (p=0.04) remained
significantly different between GDM and ND women.
Using the combined group of women (GDM and ND), partial
correlations (Table 3) and Pearson bivariate analysis
(Supplementary Table 1) were used to determine correlations
between the complement proteins and the demographic, clinical
and biochemical data and between members of the complement
system (Table 4 and Supplementary Table 2).
Using partial correlations, a correlation was found between
complement C4 and ALT (r=0.37, p=0.02) and second trimester
diastolic blood pressure (r=0.31, p=0.038); Factor-H correlated
with CRP (r=0.30, p=0.048) (Table 3).
Using Pearson bivariate analysis, a positive correlation was
found for complement C3 with age (r=0.29, p=0.04), BMI
(r=0.30, p=0.03), CRP (r=0.32, p=0.03) while there was a
negative correlation with gestational age at delivery (r=-0.29,
p=0.047) (Supplementary Table 1). Complement C4 correlated
positively with ALT (r=0.40, p=0.008), CRP (r=0.35, p=0.02) and
second trimester diastolic blood pressure (DBP) (r=0.29,
p=0.04). Factor-H correlated positively with HbA1c (r=0.32,
p=0.03) and CRP (r=0.41, p=0.005) (Supplementary Table 1).
Multiple correlations were found between complement C3,
complement C4 and Factor-H and other complement and anti-March 2021 | Volume 12 | Article 641361
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regulation (Table 4 and Supplementary Table 2).
Regression analysis of all women combined showed that the
elevation of C3 could be accounted for by age, BMI, GA, and
CRP, with CRP being the most important predictor (p=0.024).
Complement C3b/iC3b could be accounted for by second
trimester SBP. C4 could be accounted for by ALT, CRP, and
SBP. CRP predicted Factor-H elevation.
DISCUSSION
The results of this study show an elevation of Complement C3,
C4 and Factor-H in GDM versus ND control pregnant women in
the second trimester of pregnancy. Of note, the elevation in
complement factors in GDM over that of normal pregnancyFrontiers in Endocrinology | www.frontiersin.org 5could largely be accounted for by inflammation, as assessed by
CRP, suggesting that C3, C4 and Factor-H are not independently
associated with GDM.
Complement C3 has been shown to increase with normal
pregnancy (18) and fall at term (30), but their levels in the second
trimester have not been described. Also, C3 has been shown to be
further elevated in pre-eclampsia (24). Furthermore, increased C3
is associated with obesity, dyslipidaemia, inflammation, insulin
resistance and liver dysfunction (32), most of the known factors
associated with an increased risk of preeclampsia (33). Many of
these features were seen in the women with GDM who were more
obese, older, and with higher ALT levels. CRP was the greatest
predictor of an elevated C3 and, when taken into account together
with age and BMI in the regression model, then C3 was no longer
significantly elevated, suggesting that it is reflecting the GDMTABLE 1 | Demographic and biochemical data of the gestational diabetes (GDM) and control women.
Control Sample size GDM Sample size Student t-test
Mean (SD) Mean (SD) p-value
Age (years) 29.7 (4.2) 16 34.3 (4.4) 34 0.001
BMI (kg/m2) 28.4 (6.4) 16 35.3 (5.6) 34 0.0003
Systolic-BP baseline (mmHg) 108.0 (12.0) 16 114.0 (12.0) 34 0.08
Diastolic-BP baseline (mmHg) 66.0 (8.0) 16 62.0 (6.0) 34 0.075
GDM diagnosis/gestational age (weeks) 20.8 (5.2) 16 22.2 (4.1) 34 0.308
Plasma glucose (mmol/L) 4.7 (0.3) 5 5.5 (0.9) 25 0.039
Insulin (uIU/L) 0.3 (0.3) 16 0.7 (1.1) 33 0.158
Glycated hemoglobin (HbA1c) (%) 5.0 (0.4) 13 5.2 (0.3) 33 0.081
Alanine aminotransferase (U/l) 10.2 (3.6) 16 17.5 (11.8) 28 0.005
Aspartate transaminase (U/l) 15.0 (3.6) 16 18.6 (8.4) 29 0.055
Cholesterol (mmol/L) 5.2 (1.3) 11 4.9 (1.2) 19 0.501
Triglycerides (mmol/L) 1.2 (0.7) 11 1. 5 (0.9) 19 0.425
High density lipoprotein (HDL) (mmol/L) 1.6 (0.4) 11 1.3 (0.3) 19 0.051
Low density lipoprotein (LDL)(mmol/L) 3.1 (1.0) 11 2.9 (0.9) 19 0.69
C-reactive protein (CRP) (mg/l) 88.0 (86.0) 16 123 (77) 31 0.177
2nd Term Systolic Blood Pressure (mmHg) 119.0 (11.0) 16 119.0 (9.0) 33 0.837
2nd Term Diastolic Blood Pressure (mmHg) 73.0 (6.0) 16 71.0 (8.0) 33 0.571
Weight at delivery (kg) 78.2 (12.9) 16 87.4 (14.0) 33 0.036
Gestational Age at delivery (weeks) 38.4 (1.6) 16 37.9 (1.5) 33 0.341
Baby Weight (grams) 2973.0 (508.0) 16 2991.0 (589.0) 31 0.92
Premature delivery 2 16 5 32
LGA babies* 0 16 0 32March 2021 | Volume 12*LGA, large for gestational age; 90th percentile for age and was taken as 4000g.TABLE 2 | Complement and anti-complement levels in gestational diabetes (GDM) and control women.
Control (n = 16) GDM (n = 34) Unadjusted Adjusted
Mean (SD) Mean (SD) p-value p-value
Anti-Complement C2 (µg/ml) 6.9 (3.4) 7.1 (4.6) 0.89 0.29
Anti-Complement C4b (µg/ml) 12.8 (3.1) 13.3 (2.9) 0.64 0.28
Anti-Complement C5 (µg/ml) 41.2 (6.1) 40.3 (5.8) 0.62 0.91
Anti-Complement C5a (µg/ml) 0.7 (0.5) 0.8 (0.5) 0.82 0.45
Anti-Complement Factor-D (µg/ml) 2267.0 (403.0) 2148.0 (404.0) 0.33 0.22
Anti-Mannose-binding lectin (µg/ml) 2.9 (2.7) 2.5 (2.6) 0.62 0.63
Anti-complement factor-1 (µg/ml) 36.1 (6.9) 37.0 (9.7) 0.5 0.33
Complement- C1q (µg/ml) 82.4 (18.9) 80.0 (13.9) 0.63 0.62
Complement C3 (µg/ml) 162.0 (56.0) 279.0 (126.0) 0.001 0.04
Complement C3b/iC3b (µg/ml) 373.0 (270.0) 666.0 (561.0) 0.06 0.12
Complement C4 (µg/ml) 487.0 (105.0) 550.0 (96.0) 0.05 0.08
Factor-B (µg/ml) 262.0 (65.0) 293.0 (55.0) 0.08 0.19
Factor-H (µg/ml) 310.0 (66.0) 358.0 (57.0) 0.01 0.04
Properdin (µg/ml) 27.6 (6.7) 29.9 (7.7) 0.3 0.07| Article 641361
Ramanjaneya et al. Complement and Gestational Diabetesrather than being independently associated with it. Consistent
with our data, increased C3 and CRP were associated with preterm
delivery in other studies (34, 35).
Complement C4 was also elevated in GDM and associated
with CRP as a marker of inflammation but, in the regression
model accounting for CRP, ALT and SBP, then C4 was no longer
significant, mirroring the findings with C3. ALT levels were
higher in GDM, but not above the upper limit of the reference
range; however, alterations in ALT are associated with non-
alcoholic fatty liver disease which features an increase in insulin
resistance, and an elevated ALT is associated with increased risk
for GDM (36) though, notably, gamma-glutamyl transferase is a
superior predictor of GDM (37). The correlation of C4 with ALT
in GDM has not previously been reported.
C4 is associated with systolic blood pressure, and the
complement system is associated with arterial hypertensionFrontiers in Endocrinology | www.frontiersin.org 6and hypertensive end organ damage (38); however, when
adjusted for SBP, then these proteins were not significantly
different, suggesting that complement activation was not
driving the changes in blood pressure.
Factor H is a serum glycoprotein that accelerates the decay of
C3 convertase and is a cofactor for the inactivation of C3b (25).
In the absence of factor H, spontaneous activation of the
alternative pathway results (23). Factor H, in circumstances of
cell stress such as oxidative stress and hypoxia, may be
downregulated (39) and that, in turn, would contribute to any
underlying inflammatory process (40). Theoretically, the
tendency toward increased inflammation in GDM, as seen by
the trend toward CRP elevation, is mainly responsible for the
increase in C3 found in GDM. This is reflected in the increase in
the protective factor H, that correlated with CRP. Increased
oxidative stress as occurs in GDM, consequent upon the increaseTABLE 3 | Partial correlations of complement C3, complement C3b/iC3b, complement 4, and Factor-H with demographic and biochemical data for the combined
cohort (control and GDM).
Complement C3 Complement C3b/iC3b Complement C4 Factor-H
r p r p r p r p
Systolic Blood Pressure baseline (mmHg) 0.17 0.26 −002 0.90 −0.02 0.87 0.13 0.37
Diastolic Blood Pressure baseline (mmHg) −0.087 0.58 −0.06 0.70 −0.13 0.37 −0.13 0.37
GDM diagnosis/gestational age (weeks) −0.027 0.89 −0.04 0.81 0.04 0.80 −0.02 0.89
Plasma glucose (mmol/L) 0.17 0.39 −0.006 0.97 0.18 0.35 0.14 0.47
Insulin (uIU/L) −0.07 0.65 −0.18 0.23 −0.17 0.25 0.02 0.89
Glycated hemoglobin (HbA1c) (%) 0.002 0.99 0.06 0.70 0.25 0.11 0.30 0.05
Alanine aminotransferase (U/l) −0.03 0.85 0.55 0.73 0.37 0.02 0.12 0.45
Aspartate transaminase (U/l) −0.02 0.88 0.07 0.67 0.22 0.16 0.10 0.55
Cholesterol (mmol/l) −0.04 0.85 −0.03 0.88 0.12 0.55 0.24 0.23
Triglycerides (mmol/l) 0.21 0.31 −0.04 0.85 0.10 0.62 −0.05 0.80
High density lipoproteins (mmol/l) −0.21 0.30 −0.02 0.92 −0.09 0.67 −0.12 0.57
Low density lipoproteins (mmol/l) −0.05 0.79 −0.02 0.93 0.16 0.44 0.38 0.05
C-reactive protein (mg/ml) 0.24 0.12 0.19 0.21 0.24 0.12 0.30 0.048
2nd Term Systolic Blood Pressure (mmHg) −0.14 0.36 −0.26 0.08 −0.26 0.09 −0.10 0.50
2nd Term Diastolic Blood Pressure (mmHg) −0.12 0.42 −0.14 0.36 0.31 0.038 0.24 0.11
Weight at delivery (kg) −0.06 0.68 −003 0.85 −0.001 0.99 −0.07 0.66
Gestational Age at delivery (weeks) −0.19 0.20 0.05 0.76 −0.17 0.25 −0.14 0.34
Baby Weight (grams) −0.26 0.09 −0.14 0.37 −0.10 0.52 −0.25 0.11March 2021 | Volume 12 | Article 6TABLE 4 | Partial correlations of complement C3, complement C3b/iC3b, complement 4, and Factor-H with members of the complement system from the combined
cohort (control and GDM) adjusted for age and BMI.
Complement C-3 Complement C3b/iC3b Complement C4 Factor-H
r p r p r p r p
Anti-complement C2 0.33 0.03 0.57 <0.0001 0.43 0.002 0.45 0.001
Anti-Complement C4b 0.16 0.28 0.27 0.07 0.80 <0.0001 0.32 0.03
Anti-Complement C5 0.23 0.11 0.26 0.07 0.46 0.001 0.56 <0.0001
Anti-Complement C5a 0.15 0.30 0.55 <0.0001 0.35 0.02 0.14 0.34
Anti-complement Factor-D −0.20 0.18 −0.24 0.11 −0.007 0.96 0.02 0.90
Anti-Mannose-binding lectin 0.04 0.79 −0.11 0.47 0.15 0.30 0.19 0.20
Anti-complement factor-1 0.27 0.06 0.47 0.001 0.38 0.009 0.32 0.03
Complement- C1q 0.21 0.16 0.25 0.09 0.47 0.0008 0.61 <0.0001
Complement C-3 1.00 0.61 <0.0001 0.33 0.02 0.40 0.005
Complement C3b/iC3b 0.61 <0.0001 1.00 0.51 0.0002 0.43 0.002
Complement C4 0.33 0.02 0.51 0.0002 1.00 0.68 <0.0001
Factor-B 0.37 0.009 0.42 0.003 0.56 <0.0001 0.76 <0.0001
Factor-H 0.40 0.005 0.43 0.002 0.68 <0.0001 1.000
Properdin 0.28 0.054 0.26 0.08 0.44 0.002 0.62 <0.000141361
Ramanjaneya et al. Complement and Gestational Diabetesin insulin resistance (27), may reduce factor H and pathologically
increase C3 levels.
To our knowledge this is the first study to investigate all the
three complement system cascades (classical, alternative and lectin
pathway) during pregnancy in GDM subjects. Limitations of this
study include the relatively small numbers of pregnant women in
each group, which may have prevented the detection of differences
between groups. As a cross-sectional study with serum analysis at
a single time point during the second trimester, dynamic changes
in complement system proteins levels throughout pregnancy could
not be assessed. Further, the study was undertaken in a single
homogenous population and, while likely generalizable, these
findings should be confirmed in other ethnic populations.
Further studies on a suitably powered cohort of women with
GDM with and without metformin therapy would address the
question whether therapy with metformin could have any
additional impact on the inflammatory/complement proteins.CONCLUSION
In conclusion, inflammation and increased BMI associated with
GDM are likely responsible for the increased C3, C4, and Factor-
H seen in the second trimester of pregnancy in GDM that are not
independently associated with GDM, and the elevation of C3 was
negatively associated with GA; further work is needed to
determine if this is predictive.DATA AVAILABILITY STATEMENT
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